Qilian International Holding Group Limited Received Approval for Oxytetracycline API Export to Egypt

JIUQUAN,China,Oct. 13,2021 -- Qilian International Holding Group Limited(Nasdaq: QLI) (the "Company"),aChina-based pharmaceutical and chemical products manufacturer,announced that onSeptember 14,2021,through its subsidiaryGansu Qilianshan Pharmaceutical Co.,Ltd.(the"Gansu QLS"),it has received Certificate of a Pharmaceutical Product (the "Export Certificate") from Gansu Province Drug Administration,which approves the export of its Qilian Shan® Oxytetracycline APIs(Active Pharmaceutical Ingredients) (the "API")to Egypt.

The Export Certificate indicates that the Company's API isa registered pharmaceutical product approved by China,complies with relevant standards of China,islicensed for sale in Chinese market and is not subject to any export restrictions. Moreover,the productislicensed for use,and has already been used in the Egyptian market. The production facilitiesand operations also conformtothe requirements of China's GMP.

Gansu QLSwas established in 2006,and has grown to include the development,manufacture and sale of more than 20pharmaceuticalproducts,which includes three major ones,licorice products,oxytetracyclineproducts,and Traditional Chinese Medicine Derivatives(TCMD). These products have been sold to more than 20 provinces across China. Its oxytetracycline products also comply with the National Medical Products Administration (NMPA) certification,making it a strength of the company.In terms of revenue structure,oxytetracycline aremain revenue sources of the Company. In recent performance periods,oxytetracyclineand licorice products have contributed more than 60% of the Company's revenue,while oxytetracyclineproducts have accounted for more than 90% of the sales of this segment and it isthe Company's core product.

Mr. Zhanchang Xin,Chairman and CEO of the Company,commented,"We are very pleased with this good news. The approval of this direct exportinglicense marks a smooth opening tooverseas markets. So that we have a solid foundation for further export expansion in the future."

AboutQilian International Holding Group Limited

Qilian International Holding Group Limited,headquartered inGansu,is a pharmaceutical and chemical products manufacturer inChina. It focuses on the development,manufacture,marketing and sale of licorice products,oxytetracycline products,traditional Chinese medicine derivatives product,heparin product,sausage casings,and fertilizers. The Company's products are sold in more than 20 provinces inChina. For more information,visit the company's website athttp://qilianinternational.com/

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact inthis announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition,results of operations,business strategy,financial needs and the successful construction of the pig by-product processing project facility. Investors can identify these forward-looking statements by words or phrases suchas "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances,or changes in its expectations,except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable,it cannot assure you that such expectations will turn out to be correct,and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factorsthat may affect its future results in the Company's registrationstatement and in its other filings with theSEC.

For more information,please contact:

Qilian International Holding Group Limited

Email:QLI@qlsyy.net

View original content:https://www.prnewswire.com/news-releases/qilian-international-holding-group-limited-received-approval-for-oxytetracycline-api-export-to-egypt-301398838.html